Drug therapy includes glucocorticoids, interferon-alpha, vincristine, and octreotide, which stabilize the prognosis of BRBNS and reduce GI bleeding by reducing vascular endothelial cell production and proliferation.[34,36,37] Notably, sirolimus (Rapamycin) is a novel anti-angiogenic agent that has no adverse drug reactions and acts to reduce the size of venous malformations and control GI bleeding by inhibiting the mTOR signaling pathway.[38]. The gene discussed is MTOR; the disease is Venous malformation.